A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

This study is testing a new type of cell therapy called CD19/CD22/BCMA CAR-T therapy — where a patient's own immune cells are genetically re-engineered to attack multiple myeloma (a cancer of the blood/bone marrow) — in people whose myeloma has come back or stopped responding to other treatments. **You may be eligible if...** - You are 18–75 years old - You have confirmed multiple myeloma with measurable disease - Your myeloma cells carry the BCMA protein marker - You have tried and failed prior standard treatments - You are in reasonably good health (ECOG score 2 or below) - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - Your organ function (heart, liver, kidneys, lungs) is significantly impaired - You have active infections, uncontrolled autoimmune disease, or another active cancer - You have had a prior stem cell transplant or organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.